There are many approaches researchers, scientists and doctors are using to tackle cancer. One entrepreneur is engaging in a data driven approach to help treat the disease. That entrepreneur, Eric Lefkofsky, is using his business background to contribute to the fight against cancer.
Eric Lefkofsky co-founded Tempus to use data to help create precise medical solutions in the treatment of cancer. Using genomic tests, the company can analyze DNA, RNA, and proteomic data at a molecular level. That data is then able to create a custom medical treatment that can, in theory, be more effective than a broad medical cancer treatment.
In addition to analyzing patient data, Tempus looks at lab reports, clinical notes, radiology scans and pathology images to gain more data and understand the context of each patient. Once this data is collected, it is combined with other patient’s data to create an algorithm that can help refine overall cancer treatments.
In a recent interview, Eric Lefkofsky discussed his process when its comes to managing his businesses. Mr. Lefkofsky revealed that he is driven by creating a business that can change the world over a long time period. That approach allowed Mr. Lefkofsky to become more patient methodical with his business approach.
Tempus was started in 2015 by Eric Lefkofsky and Brad Keywell. The company currently collaborates with Mayo Clinic, Northwestern’s Lurie Cancer Center, Penn’s Abramson Cancer Center, University of Chicago Medicine, the Cleveland Clinic and Duke University School of Medicine to create the largest database of cancer patient data and clinical analysis. As of the fall of September 2017, Tempus has raised $130 million dollars. The company has a current value of $700 million.
Eric Lefkofsky has founded a number of companies over the past two decades. He currently serves as the Chairman of Groupon and the Co-founder and CEO of Tempus. Mr. Lefkofsky graduated from the University of Michigan with honors and received a Juris Doctor from University of Michigan Law School in 1993.